Innate immune pathway modulator screen identifies STING pathway activation as a strategy to inhibit multiple families of arbo and respiratory viruses

cGAS-STING pathway Biomedical and clinical sciences respiratory syncytial virus Immunology CHIKV 610 Antiviral Agents Article Zika virus Mice Rare Diseases WNV EV-D68 pattern-recognition receptors Biodefense 616 Genetics 2.1 Biological and endogenous factors Innate STING activator cAIMP blocks ZIKV Animals RNA Viruses Biomedical and Clinical Sciences SARS-CoV-2 Zika Virus Infection Inflammatory and immune system enterovirus-D68 Immunity COVID-19 Zika Virus Immunity, Innate 3. Good health Vector-Borne Diseases Emerging Infectious Diseases Infectious Diseases Good Health and Well Being Medical Microbiology 5.1 Pharmaceuticals antiviral activity cAIMP Infection West Nile virus Chikungunya virus scleroglucan
DOI: 10.1016/j.xcrm.2023.101024 Publication Date: 2023-04-28T14:36:13Z
ABSTRACT
RNA viruses continue to remain a threat for potential pandemics due their rapid evolution. Potentiating host antiviral pathways prevent or limit viral infections is promising strategy. Thus, by testing library of innate immune agonists targeting pathogen recognition receptors, we observe that Toll-like receptor 3 (TLR3), stimulator interferon genes (STING), TLR8, and Dectin-1 ligands inhibit arboviruses, Chikungunya virus (CHIKV), West Nile virus, Zika varying degrees. STING (cAIMP, diABZI, 2',3'-cGAMP) agonist scleroglucan demonstrate the most potent, broad-spectrum function. Furthermore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enterovirus-D68 (EV-D68) infection in cardiomyocytes. Transcriptome analysis reveals cAIMP treatment rescue cells from CHIKV-induced dysregulation cell repair, immune, metabolic pathways. In addition, provides protection against CHIKV chronic CHIKV-arthritis mouse model. Our study describes signaling circuits crucial replication identifies antivirals effective multiple families pandemic viruses.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (83)
CITATIONS (21)